News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,943 Results
Type
Article (43668)
Company Profile (473)
Press Release (693790)
Multimedia
Podcasts (122)
Webinars (20)
Section
Business (209311)
Career Advice (2038)
Deals (36151)
Drug Delivery (119)
Drug Development (83964)
Employer Resources (174)
FDA (16688)
Job Trends (15185)
News (354139)
Policy (33276)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2655)
Accelerated approval (34)
Adcomms (28)
Allergies (143)
Alliances (51113)
ALS (178)
Alzheimer's disease (1723)
Antibody-drug conjugate (ADC) (326)
Approvals (16923)
Artificial intelligence (539)
Autoimmune disease (155)
Automation (37)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (191)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (59)
Breast cancer (647)
Cancer (4907)
Cardiovascular disease (416)
Career advice (1723)
Career pathing (37)
CAR-T (291)
CDC (46)
Celiac Disease (2)
Cell therapy (775)
Cervical cancer (36)
Clinical research (71410)
Collaboration (1786)
Company closure (4)
Compensation (1170)
Complete response letters (63)
COVID-19 (2771)
CRISPR (96)
C-suite (869)
Cystic fibrosis (152)
Data (6286)
Decentralized trials (2)
Denatured (39)
Depression (142)
Diabetes (503)
Diagnostics (6742)
Digital health (46)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (265)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (242)
Earnings (91356)
Editorial (59)
Employer branding (21)
Employer resources (153)
Events (120970)
Executive appointments (1000)
FDA (19825)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1524)
Gene editing (211)
Generative AI (45)
Gene therapy (642)
GLP-1 (1009)
Government (4755)
Grass and pollen (6)
Guidances (384)
Healthcare (19202)
HIV (58)
Huntington's disease (46)
IgA nephropathy (85)
Immunology and inflammation (273)
Immuno-oncology (61)
Indications (105)
Infectious disease (3037)
Inflammatory bowel disease (197)
Inflation Reduction Act (17)
Influenza (114)
Intellectual property (247)
Interviews (315)
IPO (16931)
IRA (52)
Job creations (3712)
Job search strategy (1439)
JPM (65)
Kidney cancer (15)
Labor market (83)
Layoffs (580)
Leadership (32)
Legal (8025)
Liver cancer (93)
Longevity (14)
Lung cancer (664)
Lymphoma (380)
Machine learning (43)
Management (59)
Manufacturing (803)
MASH (169)
Medical device (13912)
Medtech (13964)
Mergers & acquisitions (20294)
Metabolic disorders (1315)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (337)
Neuropsychiatric disorders (95)
Neuroscience (3007)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4580)
Now hiring (65)
Obesity (630)
Opinion (281)
Ovarian cancer (167)
Pain (204)
Pancreatic cancer (229)
Parkinson's disease (294)
Partnered (34)
Patents (493)
Patient recruitment (492)
Peanut (56)
People (60288)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22461)
Phase 2 (31490)
Phase 3 (23275)
Pipeline (5238)
Policy (295)
Postmarket research (2602)
Preclinical (9603)
Press Release (67)
Prostate cancer (244)
Psychedelics (55)
Radiopharmaceuticals (297)
Rare diseases (885)
Real estate (6064)
Recruiting (71)
Regulatory (24971)
Reports (52)
Research institute (2484)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (21)
RSV (76)
Schizophrenia (154)
Series A (254)
Series B (202)
Service/supplier (11)
Sickle cell disease (103)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3804)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (81)
Vaccines (1021)
Venture capital (93)
Weight loss (408)
Women's health (91)
Worklife (19)
Date
Today (146)
Last 7 days (648)
Last 30 days (2253)
Last 365 days (30752)
2026 (3156)
2025 (31063)
2024 (36297)
2023 (41015)
2022 (52277)
2021 (56764)
2020 (54922)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32349)
2015 (38397)
2014 (32186)
2013 (27109)
2012 (29221)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (315)
Arkansas (14)
Asia (40687)
Australia (6759)
California (11424)
Canada (3289)
China (1134)
Colorado (484)
Connecticut (492)
Delaware (336)
Europe (89177)
Florida (1679)
Georgia (357)
Hawaii (3)
Idaho (61)
Illinois (879)
India (65)
Indiana (522)
Iowa (24)
Japan (430)
Kansas (129)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1398)
Massachusetts (8318)
Michigan (323)
Minnesota (635)
Mississippi (5)
Missouri (129)
Montana (33)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3041)
New Mexico (31)
New York (2993)
North Carolina (1527)
North Dakota (9)
Northern California (5548)
Ohio (336)
Oklahoma (21)
Oregon (45)
Pennsylvania (2291)
Puerto Rico (23)
Rhode Island (48)
South America (1121)
South Carolina (65)
South Dakota (1)
Southern California (4431)
Tennessee (174)
Texas (1759)
United States (40657)
Utah (340)
Vermont (1)
Virginia (266)
Washington D.C. (82)
Washington State (953)
West Virginia (4)
Wisconsin (113)
Wyoming (2)
737,943 Results for "dragonfly therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AbTherx and Dragonfly Therapeutics Expand Antibody Discovery Partnership
September 23, 2025
·
3 min read
Genetown
Dragonfly Therapeutics, Inc. Announces Clinical Collaboration to Evaluate DF9001, an EGFR targeting TriNKET®, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced that it has entered into a clinical collaboration with Merck, to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced solid tumors expressing EGFR.
May 21, 2024
·
3 min read
Genetown
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly’s DF1001 HER-2 TriNKET® with Gilead’s Trodelvy® in two Cancer Indications
Dragonfly Therapeutics, Inc. announced a new clinical collaboration designed to evaluate and combine DF1001, a HER-2 immune engager developed using Dragonfly’s TriNKET technology platform and Dragonfly’s lead clinical asset, with Trodelvy, Gilead’s Trop-2-directed antibody drug conjugate, in metastatic breast cancer and non-small cell lung cancer.
February 15, 2024
·
3 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
Press Releases
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
January 13, 2026
·
9 min read
Press Releases
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
February 10, 2026
·
7 min read
Press Releases
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
January 16, 2026
·
8 min read
Press Releases
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2026
February 3, 2026
·
2 min read
Press Releases
Zevra Therapeutics, Inc. Announces CFO Transition
November 21, 2025
·
3 min read
Drug Development
Dragonfly Therapeutics Initiates Phase 1/1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors
Dragonfly Therapeutics, Inc. today announced it recently dosed its first patient in a Phase 1/1b study of the Company’s proprietary IL-2 investigational immunotherapy, DF6215, developed for patients with advanced solid tumors.
December 5, 2023
·
3 min read
1 of 73,795
Next
